January 11, 2022
Via: Biopharm InternationalPfizer and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, have entered into a development and option agreement under which Pfizer will have the option to license, on a non-exclusive […]
March 30, 2023
March 28, 2023
March 23, 2023
March 16, 2023